Header Logo

Connection

Xiaoying Sun to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Xiaoying Sun has written about Antibodies, Monoclonal, Humanized.
Xiaoying Sun
Connection Strength
0.085
Antibodies, Monoclonal, Humanized
  1. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23; 370(4):311-21.
    View in: PubMed
    Score: 0.085
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.